# EDGAR Filing Document

**Accession Number:** 0001981662
**File Stem:** 0000000000-25-010579
**Filing Date:** 2025-9
**Character Count:** 6274
**Document Hash:** 1dd72c8116cbbc1a520d615bb256f1ab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-010579.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0000000000-25-010579

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250929

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NewGenIvf Group Ltd
- **CENTRAL INDEX KEY:** 0001981662
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D8

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-08362

**BUSINESS ADDRESS:**
- **STREET 1:** 13/F, PS TOWER, SUKHUMVIT 21 RD (ASOKE)
- **CITY:** BANGKOK
- **STATE:** W1
- **ZIP:** 0000
- **BUSINESS PHONE:** 852-2861-1666

**MAIL ADDRESS:**
- **STREET 1:** 1/F, PIER 2, CENTRAL
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 999077

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ASPAC I Mini Acquisition Corp.
- **DATE OF NAME CHANGE:** 20230614
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-25-079717

## Text-Extract

```

                                                            September 29, 2025

Wing Fung Alfred Siu
Chief Executive Officer
NewGenIvf Group Ltd
36/39-36/40, 13th Floor, PS Tower
Sukhumvit 21 Road (Asoke)
Khlong Toei Nuea Sub-district
Watthana District, Bangkok 10110
Thailand

       Re: NewGenIvf Group Ltd
           Registration Statement on Form F-1
           Filed September 15, 2025
           File No. 333-290284
Dear Wing Fung Alfred Siu:

       We have conducted a limited review of your registration statement and
have the
following comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form F-1 filed September 15, 2025
Recent Development
Strategic Investments in Digital Assets, page 23

1.     We note your revised disclosure in response to prior comment 1. Please
revise to
       address the following matters:

             Disclose the material terms of your custody arrangements, and file
your
           agreement with OSL Limited as an exhibit to your registration
statement if
           material.
 September 29, 2025
Page 2

             Disclose the scope and limitations of the insurance coverage that
OSL Limited
           provides and discuss whether OSL Limited   s coverage is shared by
its other
           custody customers, and whether that could result in the coverage
being
           insufficient to compensate you for losses.
             Disclose with specificity the bonding and unbonding periods
associated with
           staking SOL.
             Disclose the percentage of your SOL holdings currently staked and
whether you
           have a target percentage of your SOL holdings that you intend to
stake.
             Disclose the percentage of staking rewards earned, or to be
earned, from your
           staked SOL to which you are entitled pursuant to your staking
arrangements.
Risk Factors
Risks Related to Government Regulation
Advertising of offering gender selection services in certain jurisdictions in
which NewGenIvf
operates..., page 51

2.     We note your revisions in response to prior comment 2. You disclose that
"On April
       25, 2025, Wing Fung Alfred Siu and Hei Yue Tina Fong, and several other
       individuals were arrested in Hong Kong for allegedly violating certain
sections of the
       HRTO which prohibit using reproductive technologies for sex selection,
advertising
       sex selection services, commercial surrogacy arrangements, and
advertising surrogacy
       arrangements." Please revise this risk factor to specifically describe
with more detail
       the reasons for the arrests of certain of your officers and employees by
the relevant
       authorities in Hong Kong. Please also clarify if these charges are being
brought forth
       pursuant to the HRTO and disclose whether the charges are specific to
the company
       and/or your officers, directors and employees.
3.     In your revised disclosure, you state that you "do not advertise or
promote gender
       selection services in Hong Kong, and all such marketing activities are
carried out
       outside of Hong Kong or by agents outside of Hong Kong," and that you
"have not
       been, nor do [you] expect to be, materially impacted by any such
increased
       enforcement of the HRTO." You also state that you "do not expect any
material
       impact on our ability to generate revenue from Chinese clients, as
[y]our PRC-sourced
       revenues derived from clients in mainland China and Hong Kong are
generated
       through referrals from PRC agents, with payments being made by the
clients directly
       to the local clinics." Please expand the risk factor to describe any
consequences to you
       if the regulatory authorities in Hong Kong deems your determination
       inconsistent from the HRTO.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.
 September 29, 2025
Page 3

       Please contact Nicholas O'Leary at 202-551-4451 or Lauren Nguyen at
202-551-3642
with any other questions.

                                                       Sincerely,

                                                       Division of Corporation
Finance
                                                       Office of Industrial
Applications and
                                                       Services
cc:   Steve Lin

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._